Get the Stockscreener App
50.70
0.56%
0.28
Mirum Pharmaceuticals Inc stock is traded at $50.70, with a volume of 526.41K.
It is up +0.56% in the last 24 hours and up +12.64% over the past month.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
See More
Previous Close:
$50.42
Open:
$49.83
24h Volume:
526.41K
Relative Volume:
1.22
Market Cap:
$2.43B
Revenue:
$379.25M
Net Income/Loss:
$-77.34M
P/E Ratio:
-31.45
EPS:
-1.6122
Net Cash Flow:
$-27.87M
1W Performance:
+3.51%
1M Performance:
+12.64%
6M Performance:
+18.87%
1Y Performance:
+53.64%
1-Day Range:
$48.78
$50.95
1-Week Range:
$47.79
$50.95
52-Week Range:
$28.56
$54.23
Mirum Pharmaceuticals Inc Stock (MIRM) Company Profile
Name
Mirum Pharmaceuticals Inc
Sector
Industry
Phone
650-667-4085
Address
989 EAST HILLSDALE BOULEVARD, SUITE 300, FOSTER CITY
Compare MIRM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MIRM
Mirum Pharmaceuticals Inc
|
50.70 | 2.43B | 379.25M | -77.34M | -27.87M | -1.6122 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.99 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
508.86 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.71 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
540.71 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
254.09 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Mirum Pharmaceuticals Inc Stock (MIRM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-19-25 | Resumed | H.C. Wainwright | Buy |
| Apr-17-24 | Initiated | Stifel | Buy |
| Dec-18-23 | Reiterated | H.C. Wainwright | Buy |
| Nov-20-23 | Resumed | JP Morgan | Overweight |
| Nov-13-23 | Initiated | Morgan Stanley | Overweight |
| Oct-24-23 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-17-23 | Resumed | Evercore ISI | Outperform |
| Sep-20-23 | Initiated | JMP Securities | Mkt Outperform |
| Sep-01-22 | Initiated | Citigroup | Buy |
| Sep-20-21 | Initiated | JP Morgan | Overweight |
| Aug-07-20 | Upgrade | Raymond James | Outperform → Strong Buy |
| Aug-03-20 | Initiated | H.C. Wainwright | Buy |
| Jul-31-20 | Initiated | Piper Sandler | Overweight |
| Jun-25-20 | Initiated | Robert W. Baird | Outperform |
| Aug-12-19 | Initiated | Citigroup | Buy |
| Aug-12-19 | Initiated | Evercore ISI | Outperform |
| Aug-12-19 | Initiated | Guggenheim | Buy |
| Aug-12-19 | Initiated | ROTH Capital | Buy |
| Aug-12-19 | Initiated | Raymond James | Outperform |
View All
Mirum Pharmaceuticals Inc Stock (MIRM) Latest News
Rhumbline Advisers Purchases 2,321 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) - Defense World
Where are the Opportunities in (MIRM) - news.stocktradersdaily.com
Insider Sell: William Fairey Sells Shares of Mirum Pharmaceutica - GuruFocus
High Growth Tech Stocks In The US Market - Yahoo Finance
Cantor Fitzgerald Predicts MIRM FY2026 Earnings - Defense World
Mirum Pharmaceuticals Expands Team with 10 New Hires, Grants $5.7M Stock Options Package - Stock Titan
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
Why Is Mirum Pharmaceuticals (MIRM) Down 1.3% Since Last Earnings Report? - Yahoo Finance
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $3.06 Million Stock Position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) - Defense World
Insider Sell: Saira Ramasastry Sells 8,203 Shares of Mirum Pharm - GuruFocus
Mirum Pharmaceuticals director sells shares totaling $377,843 - Investing.com Australia
Insider Sell: Saira Ramasastry Sells 8,203 Shares of Mirum Pharmaceuticals Inc (MIRM) - GuruFocus
Mirum Pharmaceuticals director sells shares totaling $377,843 By Investing.com - Investing.com South Africa
(MIRM) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
Mirum pharmaceuticals raises 2025 revenue guidance to $435M-$450M driven by robust growth - MSN
Mirum Pharmaceuticals Holds 2025 Annual Stockholders Meeting - TipRanks
Alagille Syndrome Treatment Market Detailed in New Research ReportMirum Pharmaceuticals, Albireo Pharma - openPR.com
Two Sigma Investments LP Has $5.23 Million Stock Holdings in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) - MarketBeat
Man Group plc Invests $289,000 in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) - Defense World
Mirum Pharmaceuticals’ SWOT analysis: rare disease stock shows growth potential By Investing.com - Investing.com South Africa
Mirum Pharmaceuticals’ SWOT analysis: rare disease stock shows growth potential - Investing.com Nigeria
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Cuts Stock Holdings in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) - Defense World
When the Price of (MIRM) Talks, People Listen - news.stocktradersdaily.com
Mirum Pharmaceuticals (MIRM) – Research Analysts’ Weekly Ratings Changes - Defense World
What is HC Wainwright’s Estimate for MIRM Q2 Earnings? - Defense World
Mirum Pharmaceuticals at RBC Conference: Strategic Growth Highlights - Investing.com
Mirum Pharmaceuticals Appoints Doug Sheehy, JD, as Chief Legal Officer - citybiz
Comerica Bank Reduces Stake in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) - Defense World
Mirum Pharmaceuticals (NASDAQ:MIRM) Given “Buy” Rating at HC Wainwright - Defense World
Mirum Pharmaceuticals Names Doug Sheehy New Chief Legal Officer - Bloomberg Law News
Mirum Pharmaceuticals (MIRM) Receives Buy Rating from HC Wainwri - GuruFocus
Mirum Pharmaceuticals (MIRM) Appoints New Chief Legal Officer | - GuruFocus
Mirum Pharmaceuticals (MIRM) Receives Buy Rating from HC Wainwright & Co. | MIRM Stock News - GuruFocus
Mirum Pharmaceuticals (MIRM) Receives Buy Rating with Promising Growth Potential | MIRM Stock News - GuruFocus
Analysts Set Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Price Target at $60.64 - Defense World
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Q1 2025 Earnings Call Transcript - MSN
Northern Trust Corp Acquires 32,059 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) - Defense World
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Shares Sold by The Manufacturers Life Insurance Company - Defense World
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences - Business Wire
Mirum Pharmaceuticals (MIRM) Maintains Strong Buy Rating with Ra - GuruFocus
Mirum Pharmaceuticals (MIRM) Gets Price Target Boost to $77 | MI - GuruFocus
Trend Tracker for (MIRM) - news.stocktradersdaily.com
FY2025 EPS Estimates for MIRM Raised by Cantor Fitzgerald - Defense World
Leerink Partnrs Brokers Increase Earnings Estimates for MIRM - Defense World
JMP Securities Increases Mirum Pharmaceuticals (NASDAQ:MIRM) Price Target to $76.00 - Defense World
Mirum Pharmaceuticals (MIRM) Price Target Raised Following Stron - GuruFocus
Beyond The Numbers: 4 Analysts Discuss Mirum Pharmaceuticals Stock - Benzinga
Mirum Pharmaceuticals (MIRM) Maintains Market Outperform Rating with Higher Price Target | MIRM Stock News - GuruFocus
Mirum Pharmaceuticals Inc Stock (MIRM) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):